AI-Powered Breast Cancer Screening: Dr. J Officially Launches in Wuhan

Wuhan, September 25 — At the high-profile “2025 Japan Enterprises Visit Wuhan” economic and trade event—hosted by the Wuhan Municipal Government and joined by more than 30 top Japanese companies including Toyota and Panasonic—Guangzhou Shangyi Cloud Information Technology Co., Ltd. (Shangyi Cloud), together with its strategic shareholder Sojitz Corporation and relevant Wuhan authorities, officially signed a cooperation agreement announcing the strategic launch of the Dr. J AI Breast Cancer Screening Program in Wuhan.

This milestone marks not only Dr. J’s continued national expansion into Central China after successful deployments in multiple regions across the country, but also highlights the growing international recognition of Shangyi Cloud’s independently developed AI healthcare solutions on major global cooperation platforms.

During the event, Wuhan Mayor Sheng Yuechun met with participating company representatives, emphasizing Wuhan’s strong capabilities in scientific innovation and its open, business-friendly environment. He also expressed full support for the introduction of advanced medical technology projects such as Dr. J into Wuhan.

A highlight of this year’s event was the presentation of Dr. J’s breakthrough AI breast cancer screening solution. For years, large-scale breast cancer screening has faced two major challenges at the grassroots level: a shortage of qualified ultrasound specialists and low screening efficiency. Dr. J addresses both issues through its cutting-edge AI technology, enabling “general healthcare staff to perform scans, with AI providing expert-level diagnosis.” The system is capable of detecting subtle lesions with high precision, and real-world studies across several regions have confirmed that its breast cancer detection rate significantly outperforms traditional manual screening.

Thanks to this disruptive technological advantage and its proven social impact, the project gained strong recognition from all parties and directly facilitated the signing of this strategic cooperation agreement.

Under the newly signed agreement, Shangyi Cloud will deploy its core technology—the Dr. J AI Ultrasound Breast Cancer Early Screening Robot—in partnership with the first designated pilot district, Qiaokou District, to launch comprehensive early screening services for women of eligible age. Together, both sides aim to build a “Wuhan Model” for AI-enabled breast cancer prevention featuring early detection, early treatment, and early recovery.

During the event, Dr. Zhenzhong Zhou, Chairman of Shangyi Cloud, along with Mr. Kenichi Ariga, General Manager of Sojitz (China), also held in-depth discussions with senior leaders and clinical experts from top hospitals including Wuhan Tongji Hospital and Hubei Third People’s Hospital (Hubei Zhongshan Hospital). Medical experts expressed strong approval of the Dr. J AI screening model, recognizing its tremendous potential in strengthening primary care capabilities and improving tiered medical services.

As a strategic shareholder and long-term partner, Sojitz (China) played a pivotal role in advancing this collaboration. Leveraging its extensive industrial resources and global network, Sojitz has provided crucial strategic support for Dr. J’s entry into the Wuhan market.

Mr. Kenichi Ariga, General Manager of Sojitz (China), stated:
“Wuhan sits at the heart of China and is home to exceptional talent. We see tremendous potential for advanced technologies like Dr. J. It addresses critical unmet needs in healthcare and holds both substantial social value and strong commercial prospects.”

Looking ahead, as the project advances, Dr. J will not only provide more accessible and more accurate breast health screening services for women across Wuhan but will also use Wuhan as a regional hub to expand across Central China—contributing AI-driven strength to China’s broader breast cancer prevention and control strategy.